# DEA Marijuana Schedule Change 2026: Key Regulatory Insights

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/dea-marijuana-schedule-change-2026-regulatory-update/
> **Published:** 2026-03-14T20:40:52-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:07:36-04:00
> **Clinical Summary:** Explore the DEA marijuana schedule change 2026 and its impact on cannabis medicine with 20 key regulatory updates for clinicians and patients.

---

Policy WatchMarch 14, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.

Score 70Federal Register

[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

Regulatory Action Summary

This temporary scheduling of bromazolam (a benzodiazepine analog) in Schedule I has minimal direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), though it reflects DEA oversight of controlled substance analogs that patients might use concurrently with cannabis.

[Read more →](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011)

This DEA action schedules three synthetic opioids as Schedule I controlled substances, with no direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice or patient care.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0011)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0013)

Regulatory Summary

This DEA action schedules ethylphenidate (a stimulant) as a controlled substance, relevant to cannabis clinicians managing patients concurrently using stimulants or treating ADHD as an alternative consideration.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0013)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2024-0118-0001)

This regulatory action schedules synthetic opioids, not [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/), and has minimal direct relevance to cannabis medicine clinicians or patients unless treating co-occurring opioid use disorders.

[Read more →](https://www.regulations.gov/document/DEA-2024-0118-0001)

Score 70Regulations.gov
[Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425](https://www.regulations.gov/document/DEA-2024-0112-0001)

Regulatory Summary

DEA permit 2024-20085 authorizes controlled-biopharmaceutical importation, potentially enabling clinical access to cannabis-derived or cannabis-related pharmaceutical products for licensed practitioners and patients.

[Read more →](https://www.regulations.gov/document/DEA-2024-0112-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.regulations.gov/document/DEA-2023-0147-0003)

This regulation schedules synthetic opioid analogs but does not directly affect cannabis medicine; however, it reflects DEA enforcement priorities that may influence controlled substance scheduling policies affecting cannabinoid compounds.

[Read more →](https://www.regulations.gov/document/DEA-2023-0147-0003)

Score 70Regulations.gov
[Schedules of Controlled Substances: Rescheduling of Marijuana](https://www.regulations.gov/document/DEA-2024-0059-0001)

Regulatory Summary

The DEA rescheduled marijuana from Schedule I to Schedule III, enabling increased research opportunities and potentially facilitating clinical prescribing while maintaining federal restrictions on cannabis use.

[Read more →](https://www.regulations.gov/document/DEA-2024-0059-0001)

Score 70Regulations.gov
[Definition of Engaged in the Business as a Dealer in Firearms](https://www.regulations.gov/document/ATF_FRDOC_0001-0052)

This firearms regulation does not directly apply to cannabis clinicians or patients, as it addresses dealer licensing requirements under federal firearms law rather than cannabis medicine practice or patient access.

[Read more →](https://www.regulations.gov/document/ATF_FRDOC_0001-0052)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0006)

Regulatory Summary

The DEA placed three synthetic opioid analogs (etodesnitazene, N-pyrrolidino etonitazene, protonitazene) into Schedule I, establishing legal controls on substances unrelated to cannabis medicine or patient care.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0006)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0007)

This regulation schedules three synthetic opioids under Schedule I; it does not directly impact cannabis medicine but reflects broader controlled substance policy that may influence prescribing considerations for cannabis-using patients.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0007)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001)

The DEA classified 2-Methyl AP-237, a synthetic opioid, as Schedule I, which does not directly affect cannabis regulation but reflects broader controlled substance policy relevant to pain management alternatives clinicians may discuss.

[Read more →](https://www.regulations.gov/document/DEA-2024-0026-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I](https://www.regulations.gov/document/DEA-2023-0168-0001)

Regulatory Summary

This DEA action schedules two synthetic amphetamines as controlled substances; it has no direct relevance to cannabis clinicians or patients, as it concerns separate hallucinogenic compounds outside the cannabis therapeutic domain.

[Read more →](https://www.regulations.gov/document/DEA-2023-0168-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I](https://www.regulations.gov/document/DEA-2023-0049-0004)

Regulatory Summary

The DEA temporarily scheduled six synthetic cannabinoids as Schedule I controlled substances, restricting their availability and establishing legal consequences for possession, relevant to clinicians and patients using or considering cannabis alternatives.

[Read more →](https://www.regulations.gov/document/DEA-2023-0049-0004)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0001)

This regulatory action schedules ethylphenidate as a controlled substance, which does not directly affect cannabis medicine but establishes precedent for substance scheduling that informs how cannabis derivatives are regulated federally.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Metonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0005)

Regulatory Summary

The DEA placed metonitazene, a synthetic opioid, in Schedule I; this action does not directly affect cannabis regulation but may influence pain management discussions with cannabis-using patients.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0005)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I](https://www.regulations.gov/document/DEA-2022-0145-0004)

This regulatory action schedules certain benzodiazzoepines as controlled substances, relevant to cannabis clinicians treating anxiety or seizures who may need to coordinate care with patients using these now-restricted medications.

[Read more →](https://www.regulations.gov/document/DEA-2022-0145-0004)

Score 70Regulations.gov
[Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224](https://www.regulations.gov/document/DEA-2023-0096-0001)

Regulatory Summary

A biopharmaceutical company applied for DEA licensing to import controlled substances, enabling potential development and clinical testing of cannabis-derived medicines under federal regulatory oversight.

[Read more →](https://www.regulations.gov/document/DEA-2023-0096-0001)

Score 55Regulations.gov
[Importer of Controlled-Bright Green(2024-20083)DEA1426](https://www.regulations.gov/document/DEA-2024-0111-0001)

Regulatory Summary

DEA Import Permit 2024-20083 authorizes controlled substance importation, potentially affecting cannabis clinicians’ and patients’ access to research materials or pharmaceutical cannabinoid products through regulated supply channels.

[Read more →](https://www.regulations.gov/document/DEA-2024-0111-0001)

Score 55Regulations.gov
[Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429](https://www.regulations.gov/document/DEA-2024-0110-0001)

Regulatory Summary

DEA import authorization for Cambridge Isotope allows controlled substance research materials, potentially supporting [cannabis pharmacology](https://cedclinic.com/cannabis-tolerance-behavioral-models/) and cannabinoid analysis studies relevant to clinical development.

[Read more →](https://www.regulations.gov/document/DEA-2024-0110-0001)

Score 55Regulations.gov
[Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.](https://www.regulations.gov/document/CMS-2024-0256-0045)

CMS updates 2025 Medicare/Medicaid physician payment policies and Part B coverage, potentially affecting reimbursement rates and covered services for healthcare providers, including those treating cannabis-related conditions.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0045)

Digest-Level Clinical Commentary

 Dr. Caplan’s Take
 The rescheduling of marijuana at the federal level (item 7) amid simultaneous scheduling actions targeting novel synthetic opioids and designer drugs signals a critical inflection point where cannabis is being administratively separated from its previous categorical equivalence to hard drugs, creating genuine space for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and evidence-based prescribing practices that were previously impossible. While these regulatory changes don’t eliminate the practical challenges of federal-state legal friction and the persistent lack of robust clinical trial data, they do represent official acknowledgment that cannabis warrants distinct pharmacological consideration rather than blanket prohibition, which should encourage physicians like myself to engage more rigorously with patient [cannabinoid medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/) rather than defaulting to dismissal. The parallel crackdown on synthetic opioid analogues actually underscores why cannabis medicine practitioners need to strengthen our evidence base and clinical rigor now, before cannabis becomes another

 Clinical Perspective

The majority of these regulatory actions reflect the ongoing challenge of synthetic opioid analogs and designer drugs entering illicit markets faster than scheduling mechanisms can address them, with multiple items targeting nitazene compounds and their chemical variants that have emerged as significant contributors to overdose deaths. Only one item addresses cannabis through rescheduling, while the remainder focus on synthetic cathinones, hallucinogens, benzodiazepines, and other novel psychoactive substances, indicating that the public health burden from these synthetic drugs continues to warrant substantial regulatory attention. From a clinical standpoint, these scheduling actions represent reactive rather than preventive policy tools, as the chemical modifications highlighted here suggest that substance use disorder treatment and overdose prevention programs must remain flexible enough to address drugs that may not yet be formally scheduled.

Controlled Substances SchedulingDrug EnforcementFederal RegulationSynthetic Drugs

💬 Join the Conversation

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+March+14%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+March+14%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

 Related Articles

- [New Hampshire House Lets Marijuana Legalization And Psilocybin Therapy Bills Die Without A Vote](https://cedclinic.com/psilocybin-therapy-legislation-new-hampshire-impact/)

- [A Beginner’s Guide to Reading Cannabis Certificates of Analysis in Florida](https://cedclinic.com/certificate-of-analysis-cannabis-florida-guide/)

- [Marijuana Rescheduling Is A ‘Transitional’ Step That Must Be Followed By Banking …](https://cedclinic.com/marijuana-rescheduling-banking-reform-transitional-step/)

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Policy Watch: 27 Regulatory Updates — March 16, 2026](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/)

A comprehensive review of 27 regulatory updates including cannabis and controlled substances shortly after the March 14 report.

[Read More](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/)

[Policy Watch: 10 Regulatory Updates — March 19, 2026](https://cedclinic.com/dea-synthetic-opioid-scheduling-updates-march-2026/)

Follow-up regulatory insights focusing on cannabis and synthetic drug scheduling from mid-March 2026.

[Explore Updates](https://cedclinic.com/dea-synthetic-opioid-scheduling-updates-march-2026/)

[Policy Watch: 20 Regulatory Updates — March 12, 2026](https://cedclinic.com/cannabis-regulatory-updates-march-2026/)

Prior regulatory update providing context on cannabis and controlled substance scheduling before the March 14 report.

[View Details](https://cedclinic.com/cannabis-regulatory-updates-march-2026/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).